DURECT Corporation (DRRX)

1.31 -0.03 (-2.239%)

IEX Real-Time Price

August 17, 2018 EST.

NASDAQ Global Market : Healthcare

Prev Close 1.34

Price Open 1.33

Volume: 155,613

Avg Volume: 594,273

Market Cap: 212.22M

P/E Ratio 188790896379371200

52 Wk Range 0.75-2.55



DRRX Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-07-31
156.65M
2.46M
3.15
1.57%

2018-07-13
156.36M
2.45M
2.33
1.57%

2018-06-29
156.36M
2.4M
2.54
1.53%

2018-06-15
156.36M
1.89M
3.01
1.21%




DRRX Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-05-09
Q1 2018
N/A
-0.06 (2)
0.00
0.00

2018-05-02
Q1 2018
AMC
-0.06 (2)
-0.05
0.01

2018-03-13
Q4 2017
N/A
-0.05 (3)
0.05
0.11

2018-03-01
Q4 2017
AMC
-0.05 (2)
0.05
0.11

News

DURECT's Licensee Pain Therapeutics Receives Complete Response Letter from FDA for REMOXY® ER (oxycodone) Extended-Release Capsules CII (2018-08-06 09:22 PR Newswire)

CUPERTINO, Calif. , Aug. 6, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) reported that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for Pain Therapeutics' New Drug Appl…

 


Statistics

Shares Outstanding: 162M

Top 15 Institution Percent: 43.90

Price To Sales: 4.60

Price To Book: 7.51

Revenue: 20.75M

Gross Profit: 17.64M

Cash: 41.67M

Debt: 19.90M

Return On Assets: -1.79

Return On Equity: -7.28

Profit Margin: -2.04

Price History

Beta: 0.99

50-day Moving Avg: 1.65

200-day Moving Avg: 1.53

YTD Change: 42.36

5-day Change: -0.76

1-month Change: -16.03

3-month Change: -33.50

6-month Change: 20.18

1-year Change: -20.12

Revenue Per Share: 0.00

Revenue Per Employee: 225500.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: DURECT Corporation

Exchange: NASDAQ Global Market

Industry: Drug Manufacturers

Sector: Healthcare

Website: http://www.durect.com

Durect Corp is a biopharmaceutical company. It develops pharmaceutical products based on two categories which include new chemical entities and drug delivery programs. The lead candidate for the company is DUR-928.